Kane Biotech Issues Millions of RSUs Post-Approval

Kane Biotech (TSE:KNE) has released an update.

Kane Biotech Inc. has announced the issuance of over 4 million restricted share units (RSUs) to its directors, officers, employees, and consultants under the newly approved third amended and restated PRSU Plan. The RSUs, which are exercisable into common shares, will have varying vesting periods, with the earliest vesting occurring no sooner than 12 months from the grant date. This move comes after shareholder approval at the recent annual general and special meeting, with the PRSU Plan allowing for the issuance of up to 19% of the company’s outstanding shares as RSUs.

For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.